Plain-English translation of NCT07562659 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
After surgery for early-stage colorectal cancer, some patients have cancer DNA floating in their bloodstream—a sign the cancer may come back. This trial uses a special blood test to detect this DNA and see whether using those results to guide chemotherapy decisions helps prevent recurrence. The study will compare patients who receive personalized chemotherapy based on their blood test results to those who are closely monitored without chemotherapy.
Today, doctors often give chemotherapy to all patients with early-stage colorectal cancer, even though many will never have their cancer return. This trial aims to identify which patients truly need chemotherapy based on a blood test, so doctors can spare some patients from unnecessary treatment while giving stronger treatment to those at highest risk.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will either be monitored closely without chemotherapy or receive personalized chemotherapy based on your blood test results. You will have blood samples taken at 3 and 6 months after surgery to check for cancer DNA. If you receive chemotherapy, treatment typically lasts 6 months, with your chemotherapy plan adjusted after 3 months based on whether your blood test shows cancer DNA is clearing. Regular follow-up visits will track your progress throughout the study.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
China